The genetics of antipsychotic induced tremors: A genome-wide pathway analysis on the STEP-BD SCP sample

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 156, Issue 8, 2011, Pages 975-986

  Drago, Antonio ^a   Crisafulli, Concetta ^b   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Antipsychotic; Extrapyramidal symptom; GWAS; Pathway analysis

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; DNA; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; ANTIPSYCHOTIC INDUCED TREMOR; ARTICLE; BIPOLAR MANIA; CELL SURVIVAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG MONITORING; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LIPOGENESIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; QUALITY CONTROL; SCORING SYSTEM; TREATMENT OUTCOME; TREMOR;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BIPOLAR DISORDER; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TREMOR;

EID: 80054875166     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.31245     Document Type: Article

References (42)

1. Aberg K, et al. 2010. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 67(3): 279-282.
2. Al Hadithy AF, et al. 2009. Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: The Curacao extrapyramidal syndromes study X. Hum Psychopharmacol 24(2): 123-128.
3. Alkelai A, et al. 2009. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology 206(3): 491-499.
4. Arranz MJ, de Leon J. 2007. Pharmacogenetics and pharmacogenomics of schizophrenia: A review of last decade of research. Mol Psychiatry 12(8): 707-747.
5. Barnes TR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
6. Berk M, Dodd S. 2005. Efficacy of atypical antipsychotics in bipolar disorder. Drugs 65(2): 257-269.
7. Bolaños JP, Almeida A, Moncada S. 2010. Glycolysis: A bioenergetic or a survival pathway? Trends Biochem Sci 35(3): 145-149.
8. Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc J-L. 2011. Drug-induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord: Official J Mov Disord Soc.
9. Caligiuri MP, Peavy G. 2000. An instrumental study of the relationship between extrapyramidal signs and psychosis in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 12(1): 34-39.
10. Campbell DB, et al. 2008. Association of RGS2 and RGS5 variants with schizophrenia symptom severity. Schizophr Res 101(1-3): 67-75.
11. Correll CU, Schenk EM. 2008. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21(2): 151-156.
12. Costa e Silva JA, et al. 2001. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: Results of a multicenter, collaborative trial in Latin America. J Clin Psychopharmacol 21(4): 375-381.
13. Dlaboga D, Hajjhussein H, O'Donnell JM. 2008. Chronic haloperidol and clozapine produce different patterns of effects on phosphodiesterase-1B, -4B, and -10A expression in rat striatum. Neuropharmacology 54: 745-754.
14. Ebadi M, Srinivasan SK. 1995. Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacol Rev 47(4): 575-604.
15. Garcia-Dominguez M, et al. 2003. Ebf gene function is required for coupling neuronal differentiation and cell cycle exit. Development (Cambridge, England) 130(24): 6013-6025.
16. Gelenberg AJ, Hopkins HS. 1996. Antipsychotics in bipolar disorder. J Clin Psychiatry 57(Suppl 9): 49-52.
17. Giegling I, Drago A, Schäfer M, Möller H-J, Rujescu D, Serretti A. 2011. Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects. Prog Neuropsychopharmacol Biol Psychiatry 35: 74-77.
18. Hansen TE, Casey DE, Hoffman WF. 1997. Neuroleptic intolerance. Schizophr Bull 23(4): 567-582.
19. Higa M, et al. 2010. Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: Results from the Juntendo University Schizophrenia Projects (JUSP). Neurosci Lett 469(1): 55-59.
20. Holmans P. 2010. Statistical methods for pathway analysis of genome-wide data for association with complex genetic traits. Adv Genet 72: 141-179.
21. Kusumakar V. 2002. Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. J Clin Psychiatry 63(Suppl 10): 23-28.
22. Lencz T, Malhotra AK. 2009. Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci 11(4): 405-415.
23. Liauw SS, McIntyre RS. 2010. Atypical antipsychotic tolerability and switching strategies in bipolar disorder. Expert Opin Pharmacother 11(17): 2827-2837.
24. Liu Y-Z, et al. 2009. Genome-wide association analyses suggested a novel mechanism for smoking behavior regulated by IL15. Mol Psychiatry 14(7): 668-680.
25. McIntyre RS, Konarski JZ. 2005. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 66(Suppl 3): 28-36.
26. Novick D, et al. 2010. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: Thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol 30(5): 531-540.
27. O'Dushlaine C, et al. 2009. The SNP ratio test: Pathway analysis of genome-wide association datasets. Bioinformatics (Oxford, England) 25(20): 2762-2763.
28. Padurariu M, et al. 2010. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 479(3): 317-320.
29. Pai BN, et al. 1994. Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration. Biol Psychiatry 36(7): 489-491.
30. Pall HS, et al. 1987. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 2(8559): 596-599.
31. Purcell S, et al. 2007. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3): 559-575.
32. Sachs GS, et al. 2003. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 53(11): 1028-1042.
33. Schmitz G, Heimerl S, Langmann T. 2004. Zinc finger protein ZNF202 structure and function in transcriptional control of HDL metabolism. Curr Opin Lipidol 15(2): 199-208.
34. Simpson GM, Angus JW. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11-19.
35. Tenback DE, et al. 2006. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: A prospective analysis of 10, 000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 163(8): 1438-1440.
36. Thase ME. 2007. STEP-BD and bipolar depression: What have we learned? Curr Psychiatry Rep 9(6): 497-503.
37. Tunis SL, et al. 2000. Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies. Value Health 3(3): 232-242.
38. Turner DA, Adamson DC. 2011. Neuronal-astrocyte metabolic interactions: Understanding the transition into abnormal astrocytoma metabolism. J Neuropathol Exp Neurol 70(3): 167-176.
39. Yatham LN. 2002. The role of novel antipsychotics in bipolar disorders. J Clin Psychiatry 63(Suppl 3): 10-14.
40. Yin M, et al. 2009. Ventral mesencephalon-enriched genes that regulate the development of dopaminergic neurons in vivo. J Neurosci 29(16): 5170-5182.
41. Zai CC, et al. 2007. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiatry 12(9): 794-795.
42. Zai CC, et al. 2010. Oxidative stress in tardive dyskinesia: Genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry 34(1): 50-56.